Crystagen — Research, Dosing & Price Guide

Crystagen is a Khavinson bioregulator tripeptide (Thr-Glu-Asp) that targets the immune system, specifically T-cell function and thymic activity. It supports T-cell maturation, adaptive immune surveillance, and the thymic output that critically declines with age (thymic involution). Used in Russian anti-aging medicine to counteract immunosenescence, it helps maintain the immune competence that naturally erodes after age 40, leaving older adults increasingly vulnerable to infections, cancer, and autoimmune dysregulation.

Crystagen modulates gene expression in immune cells, particularly thymocytes and mature T-lymphocytes. The tripeptide Thr-Glu-Asp interacts with chromatin regions in thymic epithelial cells and T-cells, influencing the expression of genes critical for immune function: - **Thymic function:** Promotes thymic epithelial cell viability and function, supporting the maturation and positive selection of naive T-cells. This is crucial because thymic involution (shrinkage) is one of the primary drivers of age-related immune decline. - **T-cell differentiation:** Supports the balance between CD4+ helper and CD8+ cytotoxic T-cells, optimizing the CD4/CD8 ratio which often becomes skewed with aging. - **Cytokine regulation:** Modulates the cytokine profile, enhancing Th1 responses (IFN-γ, IL-2) important for antiviral and anticancer immunity while moderating excessive Th2 and pro-inflammatory (IL-6, TNF-α) signaling that characterizes 'inflammaging.' - **NK cell support:** May enhance natural killer cell activity, an important component of innate immunity that declines with age. Like other bioregulators, Crystagen restores age-depleted tissue-specific peptide levels, shifting immune cell gene expression toward a younger, more functional phenotype without causing immune overstimulation or autoimmune activation.

• Khavinson Institute studies showed improved CD4/CD8 T-cell ratios in elderly patients receiving Crystagen cycles, indicating restored T-cell subset balance.
• Enhanced thymic output markers in aged animal models, suggesting partial reversal of thymic involution at the functional level.
• Normalized cytokine balance — reduced pro-inflammatory cytokines (IL-6, TNF-α) while maintaining or enhancing Th1 immune responses (IFN-γ) in elderly cohorts.
• Reduced frequency of respiratory infections and improved vaccination response rates in elderly patients receiving seasonal bioregulator protocols including Crystagen.
• 30+ years of clinical use in Russian gerontology with documented safety in immunocompromised and elderly populations.

• Standard dose: 10 mg subcutaneous injection daily.
• Typical cycle: 10–20 days.
• Repeat every 3–6 months, ideally with one cycle before cold/flu season (October–November) and one in early spring.
• Can be combined with Thymosin Alpha-1 for enhanced immune support — Crystagen provides epigenetic immune restoration while TA-1 provides direct immune activation.
• Part of seasonal bioregulator anti-aging protocols alongside tissue-specific bioregulators for other systems.
• No food timing restrictions. Inject subcutaneously.

Known Side Effects

• Injection site reactions — mild and uncommon.
• No immune overstimulation or autoimmune exacerbation reported — the bioregulatory mechanism normalizes rather than amplifies immune function.
• No cytokine storm risk — unlike some immune activators, Crystagen works through gentle epigenetic modulation.
• No interference with vaccinations or antimicrobial therapy.
• Short treatment cycles minimize any theoretical risks.

Safety Profile

Crystagen has an excellent safety profile supported by decades of use in elderly and immunocompromised populations — the groups most in need of immune support and most vulnerable to immune-modulating side effects. The bioregulatory mechanism normalizes immune function rather than stimulating it non-specifically, which is critical for safety in patients with autoimmune conditions or immune dysregulation. It does not cause cytokine storms, immune overstimulation, or autoimmune flares. Contraindications: organ transplant recipients on immunosuppressive therapy (theoretical risk of altering the immune balance that suppression is designed to maintain), active autoimmune disease in flare (use during remission may be appropriate — consult immunologist), and pregnancy/breastfeeding. No drug interactions with common medications. Safe alongside antibiotics, antivirals, and standard medical treatments.

Days 1–10: No immediate subjective effects. The bioregulator is modulating gene expression in thymic and immune cells. Immune function changes are occurring at the cellular level but are not perceptible. Days 11–20: The immune epigenetic reset is establishing. No subjective changes expected during this period. Weeks 3–8 (post-cycle): Immune function improvements begin manifesting. Users may notice increased resistance to common infections, faster recovery from minor illnesses, and improved general vitality. Blood work may show improved lymphocyte counts and CD4/CD8 ratios. Months 2–6: Benefits persist throughout the inter-cycle period. Reduced frequency and severity of respiratory infections is the most commonly reported benefit. Vaccination responses may improve. Repeat cycles maintain the immune benefits and are recommended before each cold/flu season.

Prices sourced from peptides.gg marketplace. Prices may vary.